Skip to main content
. 2020 Feb 11;9(1):1721810. doi: 10.1080/2162402X.2020.1721810

Figure 3.

Figure 3.

Immune infiltration of CT26 and MC38 responding to PT-112 plus ICBs. (a,b). Percentage of CD45+ (over total live), CD11b+ (over CD45+), F4/80+ (over CD11b+), and CD11c+ (over CD11b+) cells, and CD11c+ to F4/80+ cell ratio, in CT26 (a) and MC38 (b) tumors treated with PT-112 in the context of optional PD-1 (a) or (b) PD-L1 blockage. *p < .05, **p < .01, ***p < .001 (one-way ANOVA), as compared to untreated tumors; †p < .05, ††p < .01, †††p < .001 (one-way ANOVA), as compared to tumors treated with PT-112 only; #p < .05, ##p < .01, ###p < .001 (one-way ANOVA), as compared to tumors treated with PD-1 or PD-L1 blockers only, as relevant. See also Suppl. Figure 2a. (c,d). Percentage of CD3+ (over CD45+), CD8+ (over CD3+), CD4+ (over CD3+), and CD25+FOXP3+ (over CD4+) cells, and CD8+ to CD25+FOXP3+ cell ratio, in CT26 (c) and MC38 (d) tumors treated with PT-112 in the context of optional PD-1 (c) or (d) PD-L1 blockage. *p < .05, **p < .01, ***p < .001 (one-way ANOVA), as compared to untreated tumors; †p < .05 (one-way ANOVA), as compared to tumors treated with PT-112 only; #p < .05, ##p < .01, ###p < .001 (one-way ANOVA), as compared to tumors treated with PD-1 or PD-L1 blockers only, as relevant. See also Suppl. Figure 2b.